Polyhydroxylated fullerenols regulate macrophage for cancer adoptive immunotherapy and greatly inhibit the tumor metastasis

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 4, 2016, Pages 945-954

  Tang, Jinglong ^a,b   Chen, Zhiyun ^a   Sun, Baoyun ^a   Dong, Jinquan ^a   Liu, Jing ^a   Zhou, Huige ^a   Wang, Liming ^a   Bai, Ru ^a   Miao, Qing ^a,c   Zhao, Yuliang ^a   Chen, Chunying ^a   Liu, Ying ^a  

^a NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^b PEKING UNIVERSITY   (China)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Adoptive immunotherapy; Cancer; Fullerenol; Macrophage

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; BIOLOGICAL ORGANS; CELLS; DISEASES; HYDROXYLATION; MEDICAL NANOTECHNOLOGY; PATHOLOGY; RATIONAL FUNCTIONS; TOXICITY;

ACTIVATED MACROPHAGES; ADOPTIVE IMMUNOTHERAPY; CANCER; CANCER IMMUNOTHERAPY; CLINICAL APPLICATION; EFFECTIVE APPROACHES; FULLERENOLS; MITOCHONDRIAL METABOLISM;

MACROPHAGES;

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ANTIMETASTATIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOLOGIC AGENT; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYHYDROXYLATED FULLERENOL DERIVATIVE; RANTES; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYTOKINE; FULLERENE DERIVATIVE; FULLERENOL; GADOLINIUM; NANOPARTICLE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; EXPERIMENTAL LUNG METASTASIS; FEMALE; HUMAN; HUMAN CELL; HYDRODYNAMICS; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PARTICLE SIZE; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ZETA POTENTIAL; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; MACROPHAGE; METASTASIS; MITOCHONDRION; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOKINES; FULLERENES; GADOLINIUM; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MACROPHAGES; MICE; MITOCHONDRIA; NANOPARTICLES; NEOPLASM METASTASIS; NEOPLASMS;

EID: 84961279249     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.11.021     Document Type: Article

References (38)

1. Gravitz L. Cancer immunotherapy. Nature 2013, 504:S1.
2. Couzin-Frankel J. Cancer immunotherapy. Science 2013, 342:1432-1433.
3. Kirkwood J.M., Butterfield L.H., Tarhini A.A., Zarour H., Kalinski P., Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin 2012, 62:309-335.
4. Ogino S., Galon J., Fuchs C.S., Dranoff G. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011, 8:711-719.
5. Legha S.S., Gianan M.A., Plager C., Eton O.E., Papadopoulous N.E. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer 1996, 77:89-96.
6. Rosenberg S.A., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994, 271:907-913.
7. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.
8. Gattinoni L., Powell D.J., Rosenberg S.A., Restifo N.P. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006, 6:383-393.
9. Rosenberg S.A., Lotze M.T., Muul L.M., Chang A.E., Avis F.P., Leitman S., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987, 316:889-897.
10. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., et al. Use of tumour-infiltrating lymphocytes and interleukin-2 in the immu-notherapy of 652 patients with metastatic melanoma. N Engl J Med 1988, 319:1676-1680.
11. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
12. Chen C., Xing G., Wang J., Zhao Y., Li B., Tang J., et al. Multihydroxylated [Gd@C82(OH)22]n nanoparticles: antineoplastic activity of high efficiency and low toxicity. Nano Lett 2005, 5:2050-2057.
13. 22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-α mediated cellular immunity. Biomaterials 2009, 30:3934-3945.
14. Liu Y., Chen C., Qian P., Lu X., Sun B., Zhang X., et al. Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor. Nat Commun 2015, 6:5988.
15. Jiao F., Liu Y., Qu Y., Li W., Zhou G., Ge C., et al. Studies on anti-tumor and antimetastatic activities of fullerenol in a mouse breast cancer model. Carbon 2010, 48:2231-2243.
16. 20 nanoparticles. Nanotechnology 2009, 20:415102.
17. Murray P.J., Allen J.E., Biswas S.K., Fisher E.A., Gilroy D.W., Goerdt S., et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014, 41:14-20.
18. Xu L., Liu Y., Chen Z., Li W., Liu Y., Wang L., et al. Surface-engineered gold nanorods: promising DNA vaccine adjuvant for HIV-1 treatment. Nano Lett 2012, 12:2003-2012.
19. Wang C., Xu L., Liang C., Xiang J., Peng R., Liu Z. Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis. Adv Mater 2014, 26:8154-8162.
20. Guan Q., Shi X., Shen J., Zhao G. Antimicrobial, anticancer and DNA binding studies of transition metal(II) complexes containing 2-phenyl-4-selenazole carboxylic acid. Sci China Chem 2013, 56:588-594.
21. Krukenberg K.A., Kim S., Tan E.S., Maliga Z., Mitchison T.J. Extracellular poly(ADP-ribose) is a pro-inflammatory signal for macrophages. Chem Biol 2015, 22:446-452.
22. Chen Z., Liu Y., Sun B., Li H., Dong J., Zhang L., et al. Polyhydroxylated metallofullerenols stimulate IL-1β secretion of macrophage through TLRs/MyD88/NF-κB pathway and NLRP3 inflammasome activation. Small 2014, 10:2362-2372.
23. Desmedt M., Rottiers P., Dooms H., Fiers W., Grooten J. Macrophages induce cellular immunity by activating Th1 cell responses and suppressing Th2 cell responses. J Immunol 1998, 160:5300-5308.
24. Eymard J., Lopez M., Cattan A., Bouche O., Adjizian J., Bernard J. Phase I/II trial of autologous activated macrophages in advanced colorectal cancer. Eur J Cancer 1996, 32:1905-1911.
25. Guadagno J., Xu X., Karajgikar M., Brown A., Cregan S. Microglia-derived TNFα induces apoptosis in neural precursor cells via transcriptional activation of the Bcl-2 family member Puma. Cell Death Dis 2013, 4:e538.
26. Xu L., Liu Y., Chen Z., Li W., Liu Y., Wang L., et al. Morphologically virus-like fullerenol nanoparticles act as the dual-functional nanoadjuvant for HIV-1 vaccine. Adv Mater 2013, 25:5928-5936.
27. Oyewumi M.O., Kumar A., Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 2010, 9:1095-1107.
28. Waters K.M., Masello L.M., Zanger R.C., Tarasevich B.J., Karin N.J., Quesenberry R.D., et al. Macrophage responses to silica nanoparticles are highly conserved across particle sizes. Toxicol Sci 2009, 107:553-569.
29. Park J., Lim D., Lim H., Kwon T., Choi J., Jeong S., et al. Size dependent macrophage responses and toxicological effects of Ag nanoparticles. Chem Commun 2011, 47:4382-4384.
30. Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature 2013, 496:445-455.
31. Burkholder B., Huang R.Y., Burgess R., Luo S., Jones V.S., Zhang W., et al. Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta Rev Cancer 1845, 2014:182-201.
32. Striz I., Brabcova E., Kolesar L., Sekerkova A. Cytokine networking of innate immunity cells: a potential target of therapy. Clin Sci 2014, 126:593-612.
33. Lu J., Sun L.X., Lin Z.B., Duan X.S., Ge Z.H., Xing E.H., et al. Antagonism by Ganoderma lucidum polysaccharides against the suppression by culture supernatants of B16F10 melanoma cells on macrophage. Phytother Res 2014, 28:200-206.
34. Whiteside T. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27:5904-5912.
35. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004, 4:540-550.
36. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
37. Koga M., Kai H., Egami K., Murohara T., Ikeda A., Yasuoka S., et al. Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Commun 2008, 365:279-284.
38. Hutchinson J.A., Ahrens N., Riquelme P., Walter L., Gruber M., Böger C.A., et al. Clinical management of patients receiving cell-based immunoregulatory therapy. Transfusion 2014, 54:2336-2343.